- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03708562
everlinQ Endovascular Access Systems Enhancements (EASE-2) Study
April 10, 2023 updated by: TVA Medical Inc.
Prospective, single-center study to evaluate the everlinQ endoAVF System when used to create an endoAVF in hemodialysis patients.
This study aims to investigate expansion of the percutaneous venous access location to the superficial system which may provide additional procedural benefit.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
A total of up to 50 subjects will be enrolled and will undergo an endoAVF creation procedure using the everlinQ System.
All subjects may be followed for up to 12 months post index procedure based on Investigator's discretion.
The duration of the study is expected to be approximately two (2) years.
Study Type
Interventional
Enrollment (Actual)
24
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Asunción, Paraguay
- Sanatorio Italiano
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Eligible for a native arteriovenous fistula.
- Adult (age >18 years old).
- Established, non-reversible kidney failure requiring hemodialysis (including pre-dialysis patients).
- Target vein diameter(s) at fistula site ≥ 2.0 mm.
- Target artery diameter at fistula site ≥ 2.0 mm.
- Procedural access site artery and vein diameter ≥ 2.0 mm.
- At least one superficial outflow vein diameter ≥ 2.5 mm and in communication with the perforating vein.
- Estimated life expectancy > 1 year.
- Patient is free of clinically significant conditions or illness within 30 days prior to the AV fistula that may compromise the procedure.
- Presence of an antecubital perforating vein diameter ≥ 2.0 mm.
Exclusion Criteria:
- Known central venous stenosis or central vein narrowing > 50% based on imaging on the same side as the planned AVF creation.
- Upper extremity venous occlusion(s) and/or vessel abnormality(ies) on the same side as the planned AVF creation that precludes endovascular AVF creation by the everlinQ System as deemed by the interventionalists' clinical judgment.
- Prior surgically created access in the planned treatment location.
- Functioning surgical access in the planned treatment arm.
- Pregnant women.
- New York Heart Association (NYHA) class III or IV heart failure.
- Hypercoagulable state.
- Known bleeding diathesis.
- Immunosuppression, defined as use of immunosuppressive medications used to treat an active condition.
- Documented history of drug abuse including intravenous drugs within six months of AVF creation.
- "Planned" concomitant major surgical procedure within 6 months of enrollment or previous major surgery within 30 days of enrollment.
- Currently being treated with another investigational device or drug.
- Known allergy to contrast dye which cannot be adequately pre-medicated.
- Known adverse effects to sedation and/or anesthesia which cannot be adequately pre- medicated.
- Patients who do not have an ulnar or radial artery.
- Distance between target artery and vein or other anatomical abnormality will not permit catheters to be introduced, navigated to fistula site, or allow magnets to align vessels sufficiently to create the fistula.
- Evidence of calcification in vessels at the fistula site.
- Evidence of active infections on the day of the index procedure.
- Written informed consent not obtained.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: endoAVF
|
The everlinQ device is a single-use disposable device.
The everlinQ catheter system consists of two flexible, magnetic catheters.
Once the catheters are properly inserted and aligned, the magnets contained in each catheter attract to one another, approximating the vessels while simultaneously aligning the electrode with the backstop.
Radiofrequency (RF) energy is delivered to the electrode whereby the arterio-venous fistula (AVF) is created.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Procedural Success
Time Frame: At time of procedure
|
Procedure Success was defined as successful endoAVF creation confirmed via intraprocedural angiography/fistulogram or duplex ultrasound verification performed post procedure.
|
At time of procedure
|
Adverse Event Rate
Time Frame: 3 months following endoAVF creation
|
Percentage of patients who experience one or more adverse events during the first 3 months following successful endoAVF creation.
Adverse events were site-reported and reviewed by an independent Medical Monitor and the Clinical Events Committee (CEC).
|
3 months following endoAVF creation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Primary Patency at 6 Months Post Index Procedure
Time Frame: 6 months post index procedure
|
Primary Patency was defined as the time interval between the endoAVF index procedure and the earlier of a) any intervention designed to maintain or reestablish patency, b) access thrombosis, or c) access abandonment.
Kaplan-Meier (KM) was used to analyze the data.
|
6 months post index procedure
|
Number of Participants With EndoAVF Maturation at 1, 3, and 6 Months Post Index Procedure
Time Frame: 1, 3, and 6 months post index procedure
|
Maturity of the endoAVF was defined by duplex ultrasound criteria, as described in the literature as a useful surrogate of suitability for dialysis.
Maturation was defined as duplex ultrasound flow in the brachial artery of at least 500 ml/min and a vein diameter ≥ 4mm, without significant stenosis or thrombosis.
If a subject was on hemodialysis, maturity was defined by successful dialysis with 2-needles at least once.
|
1, 3, and 6 months post index procedure
|
Time to Cannulation (Months)
Time Frame: Months from index procedure to cannulation
|
The interval of time from the index procedure to successful 2-needle cannulation of the endoAVF.
|
Months from index procedure to cannulation
|
Number of Participants With Cannulation Success at Defined Follow-up Intervals
Time Frame: 0-10 days, 11-45 days, 46-135 days, 136-210 days post index procedure
|
A subject was referred to as a 'cannulation success' with the first successful 2-needle cannulation of the endoAVF access circuit.
"Cannulation Success" was defined by at least one successful hemodialysis session through a 2-needle cannulation of the endoAVF access circuit.
"Cumulative Cannulation Success" = (Successes Through End Current Interval) / (Subjects on Dialysis at Start Current Interval + Censored Dialysis Subjects through End of Last Interval).
|
0-10 days, 11-45 days, 46-135 days, 136-210 days post index procedure
|
Percentage of Participants With Assisted Primary Patency at 6 Months
Time Frame: 6 months post index procedure
|
Defined as the interval from access placement to thrombosis or abandonment; not triggered by access circuit interventions performed in the absence of occlusion.
|
6 months post index procedure
|
Percentage of Participants With Secondary Patency at 6 Months Post Index Procedure
Time Frame: 6 months post index procedure
|
Secondary Patency was defined as the time interval between the endoAVF index procedure and a) access abandonment, or b) loss to thrombosis, irrespective of intervening surgical or endovascular interventions designed to re-establish functionality in a stenosed or thrombosed access circuit.
|
6 months post index procedure
|
Percentage of Participants With Functional Patency of the endoAVF at 6 Months Post Index Procedure
Time Frame: 6 months post index procedure
|
The interval of time from the first 2-needle dialysis utilizing the access until access abandonment (SVS Reporting Standards definition).
Functional Patency was the interval of time from the first 2-needle dialysis of the endoAVF access circuit until access abandonment.
|
6 months post index procedure
|
Number of Participants With EndoAVF Related Reintervention
Time Frame: At 6 months follow-up
|
The re-intervention rate for endoAVF (defined as any intervention required to maintain or re-establish patency) was calculated at each available follow-up visit post index procedure.
|
At 6 months follow-up
|
Percentage of Participants With Modified Primary Patency at 6 Months Post Index Procedure
Time Frame: 6 months post index procedure
|
Modified Primary Patency was defined as a measure of patency that, in addition to occlusion or reinterventions within the access circuit, also included coil embolization or open surgical ligation of outflow venous branches as failures of patency when they occur after the index procedure.
|
6 months post index procedure
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Adrian Ebner, Sanatorio Italiano, Paraguay
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 16, 2017
Primary Completion (Actual)
December 12, 2018
Study Completion (Actual)
December 12, 2018
Study Registration Dates
First Submitted
October 13, 2018
First Submitted That Met QC Criteria
October 13, 2018
First Posted (Actual)
October 17, 2018
Study Record Updates
Last Update Posted (Actual)
April 12, 2023
Last Update Submitted That Met QC Criteria
April 10, 2023
Last Verified
April 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CD-0038
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Kidney Diseases
-
3-C Institute for Social DevelopmentUniversity of North Carolina, Chapel HillCompletedChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Pediatric Kidney Disease | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage V | Chronic Kidney Disease, Stage IV (Severe) | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease, Stage IUnited States
-
American Academy of Family PhysiciansUniversity of Colorado, Denver; National Institute of Diabetes and Digestive... and other collaboratorsCompletedChronic Kidney Disease | Chronic Renal Insufficiency | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney Insufficiency, ChronicUnited States
-
Universiti Putra MalaysiaRecruitingChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Requiring Chronic DialysisMalaysia
-
Centre Hospitalier le MansLe Mans UniversiteWithdrawnFatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage3 | Chronic Kidney Failure | Chronic Kidney Disease, Stage 4 (Severe)
-
National Taiwan University HospitalCompletedChronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease Stage 1Taiwan
-
Centre Hospitalier le MansLe Mans UniversiteRecruitingFatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease Stage 3BFrance
-
University of WashingtonJohns Hopkins University; National Institute of Diabetes and Digestive and... and other collaboratorsRecruitingChronic Kidney Diseases | Acute Renal Failure | Acute Renal Injury | Acute Kidney Failure | Chronic Renal Insufficiency | Kidney Failure, Acute | Renal Insufficiency, Acute | Acute Renal Insufficiency | Acute Kidney Insufficiency | Renal Failure, Acute | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney... and other conditionsUnited States
-
University of the State of Santa CatarinaUnknownKidney Diseases | Chronic Kidney Diseases | Hemodialysis | Chronic Renal Insufficiency | Renal Dialysis | Chronic Kidney Insufficiency | Chronic Renal DiseasesBrazil
-
Texas A&M UniversityWithdrawnChronic Kidney FailureUnited States
-
Lund UniversityBaxter Healthcare Corporation; Universidad de CórdobaCompletedEnd Stage Kidney Disease | Chronic Kidney Disease Requiring Chronic DialysisArgentina
Clinical Trials on everlinQ endoAVF System
-
TVA Medical Inc.Terminated
-
TVA Medical Inc.CompletedChronic Kidney Diseases
-
C. R. BardTerminatedThe WavelinQ™ Arterio-Venous Endovascular Fistula: A Global, Post-Market Investigation (WAVE-Global)Chronic Kidney Diseases | End Stage Kidney Disease | Kidney Disease, Chronic | Kidney Failure | AV Fistula | Kidney Insufficiency | Fistulas ArteriovenousSwitzerland, Belgium, Greece
-
C. R. BardRecruitingArteriovenous Fistula | End-stage Renal Disease | Kidney Disease, End-StageUnited States
-
California Institute of Renal ResearchRecruitingCKD Stage 4 | CKD Stage 5 | CKD Stage 3United States
-
TVA Medical Inc.CompletedChronic Kidney Disease (CKD)Paraguay
-
TVA Medical Inc.CompletedChronic Kidney Disease (CKD)Paraguay
-
University of California, Los AngelesNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Not yet recruitingEnd Stage Renal Disease on DialysisUnited States
-
ResMedCompleted
-
Federal University of São PauloCompletedAdverse Reaction to Systemic AgentsBrazil